Tag results:

Publication

Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

[Nature Medicine] MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase III trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease (NAFLD) and presumed nonalcoholic steatohepatitis.

Hesperetin Derivative 2a Inhibits Lipopolysaccharide-Induced Acute Liver Injury in Mice via Downregulation of circDcbld2

[Acta Pharmacologica Sinica] Scientists investigated the mechanisms of occurrence and development of acute liver injury (ALI) in lipopolysaccharide-induced ALI mice.

A Dose-Dependent Spatiotemporal Response of Angiogenesis Elicited by Zn Biodegradation During The Initial Stage of Bone Regeneration

[Advanced Healthcare Materials] In vitro, zinc extraction promoted the proliferation and migration of HUVECs and upregulated the key gene for tube formation HIF-1α and VEGF-A, with a peak concentration of 22.5 μм.

5-Bromo-3,4-Dihydroxybenzaldehyde Stabilizes Diabetic Retinal Neurovascular Units by Inhibiting the Inflammatory Microenvironment

[Biomedicine & Pharmacotherapy] Researchers investigated the potential protective effects of 5-Bromo-3,4-dihydroxybenzaldehyde on diabetic retinopathy using primary human retinal vascular endothelial cells and retinal tissue explants.

Immune–Epithelial Cell Cross-Talk Enhances Antiviral Responsiveness to SARS-CoV-2 in Children

[EMBO Reports] In vitro, adolescent peripheral blood mononuclear cells produce more cytokines, priming A549 cells for stronger interferon responses to SARS-CoV-2.

A Single Nanobody Neutralizes Multiple Epochally Evolving Human Noroviruses by Modulating Capsid Plasticity

[Nature Communications] Researchers showed that a llama-derived nanobody M4 neutralized multiple GII.4 variants with high potency in human intestinal enteroids.

Popular